莫努匹拉韦对新冠病毒肺炎患者的疗效及安全性 - Suppr

Suppr

超能文献

Efficacy and safety of molnupiravir for COVID-19 patients.

作者信息

Fatima Maurish, Azeem Saleha, Saeed Junaid, Shahid Abia, Cheema Huzaifa Ahmad

机构信息

Department of Medicine, King Edward Medical University, Lahore, Pakistan.

Department of Medicine, Nishtar Medical University, Lahore, Pakistan.

出版信息

Eur J Intern Med. 2022 Aug;102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.

DOI:10.1016/j.ejim.2022.05.024

PMID:35649740

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9130682/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/872f/9130682/4eb54f706d6d/gr1_lrg.jpg

相似文献

Efficacy and safety of molnupiravir for COVID-19 patients.

Eur J Intern Med. 2022 Aug;102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.

Molnupiravir: A new candidate for COVID-19 treatment.

Pharmacol Res Perspect. 2022 Feb;10(1):e00909. doi: 10.1002/prp2.909.

Molnupiravir for the treatment of COVID-19.

Drugs Today (Barc). 2022 Jul;58(7):335-350. doi: 10.1358/dot.2022.58.7.3419558.

Molnupiravir in COVID-19: A systematic review of literature.

Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.

New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.

Antiviral Res. 2024 May;225:105871. doi: 10.1016/j.antiviral.2024.105871. Epub 2024 Mar 28.

Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.

J Med Virol. 2022 Jul;94(7):3006-3016. doi: 10.1002/jmv.27730. Epub 2022 Apr 2.

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.

J Microbiol Immunol Infect. 2024 Jun;57(3):396-402. doi: 10.1016/j.jmii.2024.03.002. Epub 2024 Mar 16.

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.

Future Microbiol. 2022 Mar;17(5):377-391. doi: 10.2217/fmb-2021-0252. Epub 2022 Feb 24.

[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].

Rev Esp Quimioter. 2021 Oct;34(5):402-407. doi: 10.37201/req/042.2021. Epub 2021 Apr 27.

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.

Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.

引用本文的文献

Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials.

BMJ Open. 2024 Apr 17;14(4):e074373. doi: 10.1136/bmjopen-2023-074373.

for the treatment of COVID-19 patients: A rapid systematic review and meta-analysis of randomized controlled trials.

Food Sci Nutr. 2023 Dec 27;12(3):2061-2067. doi: 10.1002/fsn3.3906. eCollection 2024 Mar.

Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis.

Front Nutr. 2023 Oct 27;10:1274122. doi: 10.3389/fnut.2023.1274122. eCollection 2023.

Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Int J Antimicrob Agents. 2023 Aug;62(2):106870. doi: 10.1016/j.ijantimicag.2023.106870. Epub 2023 May 26.

Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.

J Antimicrob Chemother. 2023 Jul 5;78(7):1586-1598. doi: 10.1093/jac/dkad132.

Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.

Clin Microbiol Infect. 2023 Aug;29(8):979-999. doi: 10.1016/j.cmi.2023.04.014. Epub 2023 Apr 20.

Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis.

Antibiotics (Basel). 2023 Feb 15;12(2):393. doi: 10.3390/antibiotics12020393.

Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.

Lancet Infect Dis. 2023 Jun;23(6):683-695. doi: 10.1016/S1473-3099(22)00873-8. Epub 2023 Feb 13.

SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments.

Vaccines (Basel). 2022 Dec 14;10(12):2145. doi: 10.3390/vaccines10122145.

Development and Validation of a Questionnaire to Assess Knowledge and Attitudes toward COVID-19 Preventive Measures in Romania.

Healthcare (Basel). 2022 Sep 21;10(10):1827. doi: 10.3390/healthcare10101827.

本文引用的文献

Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.

NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16.

Molnupiravir and Its Antiviral Activity Against COVID-19.

Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022.

Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.

Lancet Infect Dis. 2022 Aug;22(8):e231-e238. doi: 10.1016/S1473-3099(22)00119-0. Epub 2022 Mar 29.

What will be the role of molnupiravir in the treatment of COVID-19 infection?

Drugs Ther Perspect. 2021;37(12):579-580. doi: 10.1007/s40267-021-00879-2. Epub 2021 Nov 5.

Molnupiravir in COVID-19: A systematic review of literature.

Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.

Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.

Letter to the Editor in Response to Zhou et al.

J Infect Dis. 2021 Oct 28;224(8):1442-1443. doi: 10.1093/infdis/jiab362.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验